LUGPA

CME COURSE NEEDS & OBJECTIVES

LUGPA CME Program

Updates for Optimizing GU Oncology Cancer Clinics of Excellence
November 9, 2017
12:30 p.m. – 5:30 p.m.
Fairmont Chicago, Millennium Park
Chicago, Illinois


Educational Needs

The field of GU Oncology has been developing with exceptional rapidity as evidenced by the multitude of FDA approved therapies for advanced prostate, bladder and kidney cancers. Concomitantly, urology practices are recognizing the importance of providing state-of-the-art care for these patients which can involve both multidisciplinary care as well as establishing their clinics of excellence. Challenges involve providing ongoing education to address not only the most recently presented/published trial data but also how to best understand and optimize diagnosis, evaluation, therapeutic selection and patient management. Hence, the course will address these issues specifically for practices dedicated to initiating and updating their GU Oncology clinics of excellence.

Educational Objectives

At the conclusion of the 2017 LUGPA CME Program: Updates for Optimizing GU Oncology Cancer Clinics of Excellence, attendees should be able to:

  1. Review the differences in genetic testing for prostate cancer patients: germline vs somatic…how is the testing performed, who should be tested, and how to create a pathway for patient counseling.
  2. Review the importance of family history assessment for all urology patients who may have a hereditable risk for cancer.
  3. Review the appropriate indications for chemohormonal therapy for newly diagnosed advanced prostate cancer patients.
  4. Review the potential implications for use of other approved CRPC therapies after initiating chemohormonal therapy frontline.
  5. Explain the issues and needs required for urologists to administer chemotherapies, targeted oral therapies and immunotherapies for prostate, bladder, and kidney cancers.
  6. Identify the adverse event and toxicity profile in order to best establish specialists within your GU Oncology clinic of excellence who can appropriately treat these patients.
  7. Review intravesical bladder cancer therapies: how to maximize current approved treatments according to recent AUA guideline updates, and be cognizant of the plethora of high risk nonmuscle invasive bladder cancer clinical trial options (vaccines/immunotherapies) which will potentially answer this unmet need.
  8. Describe the rapidly evolving field of diagnostic imaging and the value proposition of the different imaging modalities, both older and newer, and when to order which diagnostic test

Main Menu